AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2025

Feb 14, 2025

30610_dirs_2025-02-14_8d995ea0-f33a-46ab-9170-22c515a450c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-02-12

Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-12	Common Stock	A	2047	—	Acquired	22493	Direct
2025-02-12	Common Stock	F	1068	$30.93	Disposed	21425	Direct

Footnotes

F1: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 1, 2022 (the "2022 PSUs").

F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2022 PSUs.